CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system

Anesthesia and Analgesia

Volumn 116, Issue 2, 2013, Pages 463-472

  Romero, Thiago R L ^a   Resende, Livia C ^a   Guzzo, Luciana S ^a   Duarte, Igor D G ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; GUANETHIDINE; PALMIDROL; PRAZOSIN; PROPRANOLOL; PROSTAGLANDIN E2; RAUWOLSCINE; YOHIMBINE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HYPERALGESIA; MALE; NONHUMAN; NORADRENERGIC SYSTEM; PAIN THRESHOLD; PRIORITY JOURNAL; RAT;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; DINOPROSTONE; ENDOCANNABINOIDS; ETHANOLAMINES; MALE; MORPHOLINES; NOREPINEPHRINE; PAIN MEASUREMENT; PALMITIC ACIDS; PERIPHERAL NERVES; POLYUNSATURATED ALKAMIDES; PRAZOSIN; PROPRANOLOL; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SYMPATHETIC NERVOUS SYSTEM; YOHIMBINE;

EID: 84872842122     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3182707859     Document Type: Article

References (75)

1. Hong Y, Abbott FV. Contribution of peripheral alpha 1A-adrenoceptors to pain induced by formalin or by alphamethyl-5-hydroxytryptamine plus noradrenaline. Eur J Pharmacol 1996;301:41-8
2. Birder LA, Perl ER. Expression of alpha2-adrenergic receptors in rat primary afferent neurones after peripheral nerve injury or inflammation. J Physiol (Lond) 1999;515 (Pt 2):533-42
3. Maruo K, Yamamoto H, Yamamoto S, Nagata T, Fujikawa H, Kanno T, Yaguchi T, Maruo S, Yoshiya S, Nishizaki T. Modulation of P2X receptors via adrenergic pathways in rat dorsal root ganglion neurons after sciatic nerve injury. Pain 2006;120:106-12
4. Yamamoto S, Kanno T, Yamada K, Yasuda Y, Nishizaki T. Dual regulation of heat-activated K+ channel in rat DRG neurons via alpha(1) and beta adrenergic receptors. Life Sci 2009;85:167-71
5. Romero TR, de Castro Perez A, de Francischi JN, Gama Duarte ID. Probable involvement of alpha(2C)-adrenoceptor subtype and endogenous opioid peptides in the peripheral antinociceptive effect induced by xylazine. Eur J Pharmacol 2009;608:23-7
6. Romero TR, Duarte ID. Alpha(2)-Adrenoceptor agonist xylazine induces peripheral antinociceptive effect by activation of the L-arginine/nitric oxide/cyclic GMP pathway in rat. Eur J Pharmacol 2009;613:64-7
7. Romero TR, Duarte ID. Involvement of ATP-sensitive K(+) channels in the peripheral antinociceptive effect induced by the alpha(2)-adrenoceptor agonist xylazine. J Pharmacol Sci 2009;111:323-7
8. Kaplan R, Robinson CA, Scavulli JF, Vaughan JH. Propranolol and the treatment of rheumatoid arthritis. Arthritis Rheum 1980;23:253-5
9. Levine JD, Coderre TJ, Helms C, Basbaum AI. Beta 2-adrenergic mechanisms in experimental arthritis. Proc Natl Acad Sci USA 1988;85:4553-6
10. Coderre TJ, Basbaum AI, Dallman MF, Helms C, Levine JD. Epinephrine exacerbates arthritis by an action at presynaptic B2-adrenoceptors. Neuroscience 1990;34:521-3
11. Binder W, Mousa SA, Sitte N, Kaiser M, Stein C, Schäfer M. Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue. Eur J Neurosci 2004;20:92-100
12. Kurihara J, Nishigaki M, Suzuki S, Okubo Y, Takata Y, Nakane S, Sugiura T, Waku K, Kato H. 2-Arachidonoylglycerol and anandamide oppositely modulate norepinephrine release from the rat heart sympathetic nerves. Jpn J Pharmacol 2001;87:93-6
13. Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol 2005;168:327-65
14. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996;118:2023-8
15. Niederhoffer N, Schmid K, Szabo B. The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol 2003;367:434-43
16. Pakdeechote P, Rummery NM, Ralevic V, Dunn WR. Raised tone reveals purinergic-mediated responses to sympathetic nerve stimulation in the rat perfused mesenteric vascular bed. Eur J Pharmacol 2007;563:180-6
17. Page ME, Oropeza VC, Van Bockstaele EJ. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett 2008;431:1-5
18. Oropeza VC, Page ME, Van Bockstaele EJ. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 2005;1046:45-54
19. Matsuoka Y, Sakuma M, Sugioka T, Terawaki Y, Uruno T, Kubota K. Characteristics of antinociception induced by noncatecholic phenylethylamine derivatives: the relation of endogenous norepinephrine to phenylethylamine analog-induced antinociception. Jpn J Pharmacol 1988;48:263-72
20. Lichtman AH, Martin BR. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Res 1991;559:309-14
21. Yoon MH, Choi JI. Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology 2003;99:701-7
22. Yaksh TL. Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing. Pharmacol Biochem Behav 1985;22:845-58
23. Fürst S. Transmitters involved in antinociception in the spinal cord. Brain Res Bull 1999;48:129-41
24. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002;68-69:619-31
25. Reis GM, Ramos MA, Pacheco Dda F, Klein A, Perez AC, Duarte ID. Endogenous cannabinoid receptor agonist anandamide induces peripheral antinociception by activation of ATP-sensitive K+ channels. Life Sci 2011;88:653-7
26. Green AF, Young PA. A comparison of heat and pressure analgesiometric methods in rats. Br J Pharmacol Chemother 1951;6:572-85
27. Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957;111:409-19
28. Nakamura M, Ferreira SH. A peripheral sympathetic component in inflammatory hyperalgesia. Eur J Pharmacol 1987;135:145-53
29. Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J. Inhibitory effect of anandamide on resiniferatoxin- induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 2003;73:2345-53
30. Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci 1999;65:573-95
31. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998;345: 145-53
32. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-81
33. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997;221:157-60
34. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 2009;8:403-21
35. Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci USA 2006;103:11393-8
36. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, Porreca F, Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001;93:239-45
37. Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002;96:253-60
38. Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003;119:747-57
39. Reis GM, Pacheco D, Perez AC, Klein A, Ramos MA, Duarte ID. Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide. Life Sci 2009;85:351-6
40. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci 2005;77:1685-98
41. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4
42. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 2007;173:21-30
43. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 2001;419:191-8
44. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 2006;46:101-22
45. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has antiallodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008;139:541-50
46. Hohmann AG, Briley EM, Herkenham M. Pre-and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999;822:17-25
47. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000;100:685-8
48. Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, Pertwee RG. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 2001;132:631-40
49. Gold MS, Dastmalchi S, Levine JD. 2-Adrenergic receptor subtypes in rat dorsal root and superior cervical ganglion neurons. Pain 1997;691:79-90
50. Shi TS, Winzer-Serhan U, Leslie F, Hökfelt T. Distribution and regulation of alpha(2)-adrenoceptors in rat dorsal root ganglia. Pain 2000;84:319-30
51. Khasar SG, Green PG, Chou B, Levine JD. Peripheral nociceptive effects of alpha 2-adrenergic receptor agonists in the rat. Neuroscience 1995;66:427-32
52. Lorenz W, Lomasney JW, Collins S, Regan JW, Caron MG, Lefkowitz RJ. Expression of three alpha 2-adrenergic receptor subtypes in rat tissues: implications for alpha 2 receptor classification. Mol Pharmacol 1990;38:599-603
53. Takano Y, Takano M, Yaksh TL. The effect of intrathecally administered imiloxan and WB4101: possible role of alpha 2-adrenoceptor subtypes in the spinal cord. Eur J Pharmacol 1992;219:465-8
54. Piletz JE, Zhu H, Chikkala DN.comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther 1996;279:694-702
55. Fairbanks CA, Wilcox GL. Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. J Pharmacol Exp Ther 1999;290:403-12
56. Stone LS, MacMillan LB, Kitto KF, Limbird LE, Wilcox GL. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci 1997;17:7157-65
57. Hunter JC, Fontana DJ, Hedley LR, Jasper JR, Lewis R, Link RE, Secchi R, Sutton J, Eglen RM. Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol 1997;122:1339-44
58. Matsuoka Y, Sugioka T, Terawaki Y, Uruno T, Kubota K. Characteristics of antinociception induced by noncatecholic phenylethylamine derivatives: the involvement of alpha-2-adrenoceptors. Jpn J Pharmacol 1993;63:101-8
59. Nicholson R, Dixon AK, Spanswick D, Lee K. Noradrenergic receptor mRNA expression in adult rat superficial dorsal horn and dorsal root ganglion neurons. Neurosci Lett 2005;380:316-21
60. Xie J, Ho Lee Y, Wang C, Mo Chung J, Chung K. Differential expression of alpha1-adrenoceptor subtype mRNAs in the dorsal root ganglion after spinal nerve ligation. Brain Res Mol Brain Res 2001;93:164-72
61. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5
62. Choi B, Rowbotham MC. Effect of adrenergic receptor activation on post-herpetic neuralgia pain and sensory disturbances. Pain 1997;69:55-63
63. Khasar SG, McCarter G, Levine JD. Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol 1999;81:1104-12
64. Ali Z, Raja SN, Wesselmann U, Fuchs PN, Meyer RA, Campbell JN. Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain. Pain 2000;88:161-8
65. Pluteanu F, Ristoiu V, Flonta ML, Reid G. Alpha(1)-adrenoceptor-mediated depolarization and beta-mediated hyperpolarization in cultured rat dorsal root ganglion neurones. Neurosci Lett 2002;329:277-80
66. Khodayar MJ, Shafaghi B, Naderi N, Zarrindast MR. Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions. J Psychopharmacol (Oxford) 2006;20:67-74
67. Page ME. The promises and pitfalls of reboxetine. CNS Drug Rev 2003;9:327-42
68. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005;38:177-88
69. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP Jr. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 2005;102:3093-8
70. Magina S, Esteves-Pinto C, Moura E, Serräo MP, Moura D, Petrosino S, Di Marzo V, Vieira-Coelho MA. Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB(1) receptors: a keratinocyte-dependent effect. Arch Dermatol Res 2011;303:201-10
71. Flierl MA, Rittirsch D, Sarma JV, Huber-Lang M, Ward PA. Adrenergic regulation of complement-induced acute lung injury. Adv Exp Med Biol 2008;632:93-103
72. Schallreuter KU. Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. J Investig Dermatol Symp Proc 1997;2:37-40
73. Steenhuis P, Huntley RE, Gurenko Z, Yin L, Dale BA, Fazel N, Isseroff RR. Adrenergic signaling in human oral keratinocytes and wound repair. J Dent Res 2011;90:186-92
74. Hudson BD, Hébert TE, Kelly ME. Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol 2010;160:627-42
75. Sawynok J. The 1988 Merck Frosst Award. The role of ascending and descending noradrenergic and serotonergic pathways in opioid and non-opioid antinociception as revealed by lesion studies. Can J Physiol Pharmacol 1989;67: 975-88